Ezetimibe + atorvastatin

Ezetimibe + atorvastatin has been studied in 9 papers since 2017: 6 trials and 1 observational study in people, 2 reviews; 5 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Ezetimibe Plus Atorvastatin versus Double-Dose Atorvastatin Monotherapy for Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials”.

InterventionApproved 2013

9 papers study it24 more mention it20 findingsUpdated

PubChemPubChemChEBIChEBI

10 new papers in 30 daysSee all 33 papers on ezetimibe + atorvastatin

At a glance

Independent labs found the same change in people. 7 independent labs in 4 countries; 116 trials, 61 about aging, 60 with no results posted.

“AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”
Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysisPeerJ2026doi:10.7717/peerj.21784

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 7 independent labs in 4 countries
  • 116 trials, 61 about aging, 60 with no results posted
  • Funder: Organon
  • 6 of 20 findings with company ties
  • 1 of 116 trials sponsored by its developers
  • Human trial6
  • Humans1

7 studies gave ezetimibe + atorvastatin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases LDL-CMD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone

up: Increases LDL-C goal attainmentRR 1.87 (95% CI 1.47-2.39)

no change: Has no effect on adverse events

Review of trials10,567 people pooledPatient cohortsPeerJ, Oct 21, 2026

down: Decreases LDL-CLDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks

up: Increases LDL-C goal attainment

no change: Has no effect on adverse events

Randomized trial4 weeks254 peoplePatient cohortsThe Journal of the Association of Physicians of India, Mar 1, 2026

down: Decreases LDL-CWeek 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001

no change: Has no effect on adverse event incidence

Randomized trial6 weeks137 people≥ 30 yearsVery high-risk ASCVDBMC cardiovascular disorders, Feb 11, 2026

up: Increases LDL-C goal attainment62.7% vs. 35.1%, P = 0.0009

Randomized trial12 weeksBothOlder adults; cohort AAdvances in therapy, Jan 19, 2026

down: Decreases low-density lipoprotein cholesterolLSMD -21.22 (95% CI -29.26 to -13.19) at week 6 vs atorvastatin

up: Increases LDL-C goal achievement46.2% vs 9.0% at week 6; 55.0% vs 15.4% at week 12

no change: Has no effect on safety profile

Randomized trial6 weeks137 peoplemean 65.0 (SD 10.35) yearsPatient cohortsAHA Scientific Sessions 2025 abstract, Nov 3, 2025

What did studies of ezetimibe + atorvastatin find?

15

Studies of ezetimibe + atorvastatin measured 15 outcomes, among them adverse events, LDL-C and LDL-C goal attainment.

Adverse events

no changein humans3

3 studies
  1. Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (compared with atorvastatin monotherapy).

    “Treatment with AS/EZ FEC or FDC did not increase the risk of adverse events compared to AS monotherapy and was well tolerated.”

    Human trialcompared with atorvastatin monotherapy

    Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis

    PeerJ

  2. Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (compared with atorvastatin alone).

    “Adverse events were similar in both groups.”

    Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily

    Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

    The Journal of the Association of Physicians of India

  3. Ezetimibe + atorvastatin showed no clear effect on adverse events in humans (hypercholesterolemia; compared with double-dose atorvastatin) (18.2% versus 17.5%; p=0.56).

    “Safety outcomes were similar (18.2% vs. 17.5% adverse events; p=0.56).”

    Reviewhypercholesterolemia; compared with double-dose atorvastatinezetimibe 10 mg plus atorvastatin at half the comparator dose56% malesn = 5,924

    Ezetimibe Plus Atorvastatin versus Double-Dose Atorvastatin Monotherapy for Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

LDL-C

downin humans3

3 studies
  1. Ezetimibe + atorvastatin decreases LDL-C in humans (versus atorvastatin monotherapy) (MD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone).

    “AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”

    Human trialversus atorvastatin monotherapyfixed-dose combination

    Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis

    PeerJ

  2. Ezetimibe + atorvastatin decreases LDL-C in humans (compared with atorvastatin alone) (LDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks).

    “29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001)”

    Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 weeks

    Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

    The Journal of the Association of Physicians of India

  3. Ezetimibe + atorvastatin decreases LDL-C in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy) (Week 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001).

    “The EZ/AS lipid-lowering effect was statistically greater than AS monotherapy at week 6 (LSMD: -21.2; P < 0.0001) and week 12 (LSMD: -16.0; P < 0.0001).”

    Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily6 weeksn = 137

    The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease

    BMC cardiovascular disorders

More on LDL-C

LDL-C goal attainment

upin humans2RR 1.87

2 studies
  1. Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (free-equivalent combination vs atorvastatin monotherapy) (RR 1.87 (95% CI 1.47-2.39)).

    “For LDL-C goal attainment, the RR was 1.87 (95% CI [1.47-2.39]) for FEC vs. monotherapy”

    Human trialfree-equivalent combination vs atorvastatin monotherapyfree-equivalent combination

    Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis

    PeerJ

  2. Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (compared with atorvastatin alone).

    “with a markedly higher proportion of participants achieving LDL-C goals at 4 and 12 weeks”

    Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 and 12 weeks

    Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

    The Journal of the Association of Physicians of India

More on LDL-C goal attainment

LDL cholesterol

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases LDL cholesterol in humans (hypercholesterolemia; compared with double-dose atorvastatin) (-14.6% versus double-dose atorvastatin).

    “At 8 weeks, combination therapy reduced LDL-C more (-14.6%; p<0.001; I 2 =28%).”

    Reviewhypercholesterolemia; compared with double-dose atorvastatinezetimibe 10 mg plus atorvastatin at half the comparator dose8 weeks56% malesn = 5,924

    Ezetimibe Plus Atorvastatin versus Double-Dose Atorvastatin Monotherapy for Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

More on LDL cholesterol

Adverse event incidence

no changein humans1

1 study
  1. Ezetimibe + atorvastatin showed no clear effect on adverse event incidence in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy).

    “Incidence of adverse events were comparable between EZ/AS and AS groups.”

    Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily12 weeksn = 137

    The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease

    BMC cardiovascular disorders

LDL-C goal attainment

upin humans1

1 study
  1. Ezetimibe + atorvastatin increases LDL-C goal attainment in humans (cohort A) (62.7% vs. 35.1%, P = 0.0009).

    “LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001).”

    Human trialcohort A12 weeks

    LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial

    Advances in therapy

Safety profile

no changein humans1

1 study
  1. Ezetimibe + atorvastatin showed no clear effect on safety profile in humans (compared with atorvastatin monotherapy at weeks 6 and 12).

    “The safety profile was comparable between the groups at week 6 and week 12.”

    Human trialcompared with atorvastatin monotherapy at weeks 6 and 1210/40 mg10/40 mg12 weeksn = 137

    The Role of Early Ezetimibe Combination with Atorvastatin in Patients with Atherosclerotic Cardiovascular Disease

    AHA Scientific Sessions 2025 abstract

LDL-C goal achievement

upin humans1

1 study
  1. Ezetimibe + atorvastatin increases LDL-C goal achievement in humans (compared with atorvastatin monotherapy at week 6) (46.2% vs 9.0% at week 6; 55.0% vs 15.4% at week 12).

    “Significantly higher proportions of patients achieved target LDL-C levels <55 mg/dL in EZ/AS group compared with AS group at week 6 (46.2% vs. 9.0%; P <0.0001)”

    Human trialcompared with atorvastatin monotherapy at week 610/40 mg10/40 mg6 weeksn = 137

    The Role of Early Ezetimibe Combination with Atorvastatin in Patients with Atherosclerotic Cardiovascular Disease

    AHA Scientific Sessions 2025 abstract

More on LDL-C goal achievement

Low-density lipoprotein cholesterol

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases low-density lipoprotein cholesterol in humans (compared with atorvastatin monotherapy at week 6) (LSMD -21.22 (95% CI -29.26 to -13.19) at week 6 vs atorvastatin).

    “Lipid-lowering efficacy was significantly greater with EZ/AS compared with AS monotherapy at Week 6 (LS mean difference [LSMD]: -21.22; 95% CI: -29.26, -13.19; P <0.0001)”

    Human trialcompared with atorvastatin monotherapy at week 610/40 mg10/40 mg6 weeksn = 137

    The Role of Early Ezetimibe Combination with Atorvastatin in Patients with Atherosclerotic Cardiovascular Disease

    AHA Scientific Sessions 2025 abstract

More on Low-density lipoprotein cholesterol

Total bilirubin

upin humans1

1 study
  1. Ezetimibe + atorvastatin increases total bilirubin in humans.

    “Total bilirubin, DBIL, and IBIL were higher in the combined group than in the control group (P < .05).”

    Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112

    Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment

    Alternative therapies in health and medicine

More on Total bilirubin

Inflammatory factors

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases inflammatory factors in humans.

    “Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”

    Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112

    Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment

    Alternative therapies in health and medicine

More on Inflammatory factors

Lipid function

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases lipid function in humans.

    “Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”

    Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112

    Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment

    Alternative therapies in health and medicine

More on Lipid function

Blood glucose

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases blood glucose in humans.

    “Glucose, lipid function, and inflammatory factors were lower in the combined group than in the control group (P < .05).”

    Human trialin elderly patients with hypertension and type 2 diabetes mellitus, versus atorvastatin alonen = 112

    Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment

    Alternative therapies in health and medicine

More on Blood glucose

Alanine aminotransferase elevation

downin humans1

1 study
  1. Ezetimibe + atorvastatin decreases alanine aminotransferase elevation in humans (versus double-dose atorvastatin 20 mg/d) (2.8% vs. 9.0%).

    “The patients whose alanine aminotransferase increasing more than upper normal limit in combined group was lower than double-dose atorvastatin group (2.8% vs. 9.0%, p = 0.05).”

    Human trialversus double-dose atorvastatin 20 mg/datorvastatin 10 mg + ezetimibe 10 mg vs atorvastatin 20 mg

    Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome

    Oncotarget

More on Alanine aminotransferase elevation

Major adverse cardiovascular events

no changein humans1HR 1.12

1 study
  1. Ezetimibe + atorvastatin showed no clear effect on major adverse cardiovascular events in humans (Cox regression versus double-dose atorvastatin 20 mg/d) (HR 1.12 (95% CI 0.51–2.55)).

    “the risk of major adverse cardiovascular events in combined group isn't significantly higher than double-dose atorvastatin group (HR [95% CI] 1.12 [0.51 to 2.55], p = 0.74)”

    Human trialCox regression versus double-dose atorvastatin 20 mg/datorvastatin 10 mg + ezetimibe 10 mg vs atorvastatin 20 mgone year

    Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome

    Oncotarget

Has ezetimibe + atorvastatin been tested in people?

61 of 116 about aging

Yes: 6 trials and 1 observational study in people have been published, and 58 trials are registered.

Approved

Every condition in trials

All 28

Who is developing ezetimibe + atorvastatin?

2 companies: Organon and Daiichi Sankyo.

Companies
  • OrganonPhase 4atherosclerosis, primary hypercholesterolemia
  • Daiichi SankyoPhase 3coronary atherosclerosis, mixed dyslipidemia

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 3Mar 2026: 2Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 7Nov 2026: 321 papers in 12 months

See all 33 papers on ezetimibe + atorvastatin